IoM’s Drug Safety Cmte. Will Meet In June; Panel Includes Ex-FDAer Ellenberg
This article was originally published in The Tan Sheet
The Institute of Medicine's Drug Safety Committee will convene June 8 to begin discussing its review of FDA's post-marketing oversight system
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC